Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.